RAPT Therapeutics: Promising Pipeline and Superior Efficacy of Lead Candidate Ozureprubart

Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on RAPT Therapeutics and keeping the price target at $72.00.

Emily Bodnar’s rating is based on the promising potential of RAPT Therapeutics’ lead candidate, ozureprubart, which has shown a significantly longer half-life compared to omalizumab, potentially allowing for less frequent dosing. The Phase 2 trial results in chronic spontaneous urticaria (CSU) demonstrated promising efficacy, with a higher percentage of complete response scores compared to omalizumab, suggesting superior efficacy with less frequent dosing.
Additionally, the company is preparing for a Phase 3 trial, with the possibility of accelerated approval due to recent FDA guidance. The upcoming asthma data readout and the initiation of a new trial in food allergy further bolster the company’s pipeline, making RAPT a compelling investment opportunity.